Disposition of [3H]actinomycin D in tumor-bearing mice.
A single, nonlethal dose of actinomycin D will cause total regression and cure of Ridgway osteogenic sarcoma in mice. A cure is not obtained with a single dose daily for 7 days, a dose regimen which kills 10% of normal C57BL/6 X DBA/2 mice. This suggests that actinomycin D is more effective on a single high-dose schedule than on chronic daily therapy. Analysis of drug exposure in Ridgway osteogenic sarcoma and normal mouse tissues following the single and multiple-dose regimens suggests the difference in therapeutic response is due to drug exposure at a higher concentration in Ridgway osteogenic sarcoma after the single high dose than after the multiple-dose regimen. This may be related to the higher drug concentration attained in blood following the single-dose regimen than is attained with the multidose regimen.
D000818:Animals; D003609:Dactinomycin / Q000097:blood / Q000378:metabolism* / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D012516:Osteosarcoma / Q000378:metabolism*; D012044:Regression Analysis; D012513:Sarcoma, Experimental / Q000378:metabolism
D003609:Dactinomycin